Creative Biolabs is a leading company focusing on non-IgG therapeutics antibodies development. Based on years of experience and advanced platform, now we have launched a series of chimeric antibody engineering services for multiple antibody types, including but not limited to chimeric IgA antibody.
Introduction of Chimeric IgA Antibody
IgA is the second most prevalent antibody in human serum and the most predominant antibody isotype in mucosal secretions, where it serves as the first line of defense and protects against pathogens that are ingested or inhaled. Studies have shown that IgA antibodies could effectively trigger respiratory burst and phagocytosis of various microbial pathogens by human leukocytes and be exceptionally effective in recruiting polymorphonuclear cells (PMN) for antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells. Moreover, IgA has been reported to combat certain infectious and malignant diseases. Though numerous laboratory and clinical researches are being widely explored, IgA antibodies as therapeutics for human use still has a long way to go. Major drawbacks are that IgA forms in human serum are different from those in most animal species and the lack of an IgA receptor homolog in mice, which result in challenges in in vivo efficacy evaluation of therapeutic IgA antibodies. To overcome these shortcomings, multiple engineering approaches have been tried and utilized to improve the properties of recombinant monoclonal IgA antibodies, among which chimerism of IgA antibody is a typical modification.
Fig.1 Human IgA structure. (Woof, 2011)
Approaches for Chimeric IgA Antibody Production
The production of chimeric IgA antibodies usually adopts recombinant DNA technology due to the fusion of two species. Chimeric IgA antibodies production requires a sophisticated expression system capable of performing extensive post-translational modifications. Exactly, IgA production has been successfully demonstrated in our Expression System Platform, such as mammalian, insect, and plant cells. Especially, Chinese Hamster Ovary (CHO) cells are the most extensively applied host for recombinant IgA production. However, upstream processing of recombinant IgA seems to be in its infancy still, as the reported cultures are mostly conducted in simple batch mode and the working volumes are far from liter scale. During the past years, tremendous efforts have been devoted at Creative Biolabs to further optimize the applied medium formulation and develop more advanced process strategies to boost IgA titers and increase the process output to yield the desired amounts.
Chimeric IgA Antibody Production Services Provided by Creative Biolabs
Aided by our top technology platform and professional scientists, Creative Biolabs offers a series of high-quality chimeric IgA antibody production and development services with the most cost-effective price. The services we offer include but are not limited to:
- Transient transfection of stable CHO cell culture
- Serum-free cell culture
- Fed-batch culture
- IgA antibodies are expressed as a dimer linked by a J-chain
- Chimeric antibodies fused from two different species of your choice
Creative Biolabs is committed to accelerating the rapid development of our clients' programs. In addition to IgA, we also provide other chimeric antibody production and related services for global customers. For more detailed information, please feel free to contact us or send us an inquiry directly.
Reference
- Woof, J.M.; Russell, M.W. Structure and function relationships in IgA. Mucosal Immunology. 2011, 4(6): 590.
KINDLY NOTE
!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.